Michael Thase

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. doi request reprint Antidepressant combinations: cutting edge psychopharmacology or passing fad?
    Michael E Thase
    Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    Curr Psychiatry Rep 15:403. 2013
  2. ncbi request reprint The cardiovascular safety profile of escitalopram
    Michael E Thase
    Perelman School of Medicine, University of Pennsylvania School of Medicine, Suite 689, 3535 Market Street, Philadelphia, PA 19104, USA Electronic address
    Eur Neuropsychopharmacol 23:1391-400. 2013
  3. ncbi request reprint The multifactorial presentation of depression in acute care
    Michael E Thase
    3535 Market St, Ste 670, Philadelphia, PA 19104
    J Clin Psychiatry 74:3-8. 2013
  4. doi request reprint Quetiapine XR monotherapy in major depressive disorder: a pooled analysis to assess the influence of baseline severity on efficacy
    Michael E Thase
    Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    Int Clin Psychopharmacol 28:113-20. 2013
  5. doi request reprint Social skills training for depression and comparative efficacy research: a 30-year retrospective
    Michael E Thase
    Perelman School of Medicine, University of Pennsylvania, 3535 Market St, Suite 670, Philadelphia, PA 19104, USA
    Behav Modif 36:545-57. 2012
  6. ncbi request reprint The role of monoamine oxidase inhibitors in depression treatment guidelines
    Michael E Thase
    Department of Psychiatry, Perelman School of Medicine of University of Pennsylvania, Philadelphia Veterans Affairs Medical Center, Philadelphia and Pittsburgh, USA
    J Clin Psychiatry 73:10-6. 2012
  7. doi request reprint Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression
    Michael E Thase
    Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Depress Anxiety 29:574-86. 2012
  8. doi request reprint Aripiprazole in bipolar depression: a pooled, post-hoc analysis by severity of core depressive symptoms
    Michael E Thase
    University of Pennsylvania, School of Medicine, Philadelphia, PA 19104, USA
    Int J Psychiatry Clin Pract 16:121-31. 2012
  9. ncbi request reprint Are SNRIs more effective than SSRIs? A review of the current state of the controversy
    Michael E Thase
    University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Psychopharmacol Bull 41:58-85. 2008
  10. doi request reprint Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies
    Michael E Thase
    University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Clin Psychopharmacol 28:13-20. 2008

Research Grants

  1. PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSION
    Michael Thase; Fiscal Year: 2009
  2. PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSION
    Michael Thase; Fiscal Year: 2000
  3. PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSION
    Michael E Thase; Fiscal Year: 2010
  4. PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSION
    Michael Thase; Fiscal Year: 2007
  5. Are Cognitive Therapy's Antidepressant Effects Durable?
    Michael Thase; Fiscal Year: 2007
  6. PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSION
    Michael Thase; Fiscal Year: 2006
  7. Are Cognitive Therapy's Antidepressant Effects Durable?
    Michael Thase; Fiscal Year: 2006
  8. PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSION
    Michael Thase; Fiscal Year: 2005
  9. PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSION
    Michael Thase; Fiscal Year: 2004
  10. Are Cognitive Therapy's Antidepressant Effects Durable?
    Michael Thase; Fiscal Year: 2005

Collaborators

Detail Information

Publications112 found, 100 shown here

  1. doi request reprint Antidepressant combinations: cutting edge psychopharmacology or passing fad?
    Michael E Thase
    Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
    Curr Psychiatry Rep 15:403. 2013
    ..Moreover, aside from selected cases of drug-drug interactions, it may take full therapeutic doses of both drugs across a typically adequate duration of exposure to achieve the desired effects of combined treatment. ..
  2. ncbi request reprint The cardiovascular safety profile of escitalopram
    Michael E Thase
    Perelman School of Medicine, University of Pennsylvania School of Medicine, Suite 689, 3535 Market Street, Philadelphia, PA 19104, USA Electronic address
    Eur Neuropsychopharmacol 23:1391-400. 2013
    ....
  3. ncbi request reprint The multifactorial presentation of depression in acute care
    Michael E Thase
    3535 Market St, Ste 670, Philadelphia, PA 19104
    J Clin Psychiatry 74:3-8. 2013
    ..Although depression specifiers and subtypes are subject to revision and change, many of them provide helpful information about recognition and treatment. ..
  4. doi request reprint Quetiapine XR monotherapy in major depressive disorder: a pooled analysis to assess the influence of baseline severity on efficacy
    Michael E Thase
    Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    Int Clin Psychopharmacol 28:113-20. 2013
    ..Quetiapine XR monotherapy showed antidepressant effects in patients with major depressive disorder across different levels of baseline severity...
  5. doi request reprint Social skills training for depression and comparative efficacy research: a 30-year retrospective
    Michael E Thase
    Perelman School of Medicine, University of Pennsylvania, 3535 Market St, Suite 670, Philadelphia, PA 19104, USA
    Behav Modif 36:545-57. 2012
    ....
  6. ncbi request reprint The role of monoamine oxidase inhibitors in depression treatment guidelines
    Michael E Thase
    Department of Psychiatry, Perelman School of Medicine of University of Pennsylvania, Philadelphia Veterans Affairs Medical Center, Philadelphia and Pittsburgh, USA
    J Clin Psychiatry 73:10-6. 2012
    ..The availability of a safer and more tolerable formulation gives clinicians another option in their armamentarium for treating depression...
  7. doi request reprint Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression
    Michael E Thase
    Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Depress Anxiety 29:574-86. 2012
    ....
  8. doi request reprint Aripiprazole in bipolar depression: a pooled, post-hoc analysis by severity of core depressive symptoms
    Michael E Thase
    University of Pennsylvania, School of Medicine, Philadelphia, PA 19104, USA
    Int J Psychiatry Clin Pract 16:121-31. 2012
    ..placebo on treatment outcomes based on baseline severity of core depressive symptoms in patients with bipolar I disorder...
  9. ncbi request reprint Are SNRIs more effective than SSRIs? A review of the current state of the controversy
    Michael E Thase
    University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Psychopharmacol Bull 41:58-85. 2008
    ..Nevertheless, differences in tolerability and cost also must be considered when choosing therapies...
  10. doi request reprint Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies
    Michael E Thase
    University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    J Clin Psychopharmacol 28:13-20. 2008
    ..8% vs 35.1%) and Study 2 (41.2% vs 29.8%). Aripiprazole monotherapy-as dosed in this study design-was not significantly more effective than placebo in the treatment of bipolar depression at end point (Week 8)...
  11. ncbi request reprint STEP-BD and bipolar depression: what have we learned?
    Michael E Thase
    University of Pennsylvania School of Medicine, 3535 Market Street, Suite 670, Philadelphia, PA 19104, USA
    Curr Psychiatry Rep 9:497-503. 2007
    ..The STEP-BD results highlight the challenge of treating bipolar depression to remission, illustrate the value of adjunctive psychotherapies, and point to new directions for research...
  12. doi request reprint A randomized, double-blind, placebo-controlled study of the effect of sustained-release bupropion on blood pressure in individuals with mild untreated hypertension
    Michael E Thase
    Department of Psychiatry, University of Pennsylvania School of Medicine, 3535 Market Street, Philadelphia, PA 19104, USA
    J Clin Psychopharmacol 28:302-7. 2008
    ..28 vs -0.64 beats/min; Delta = 2.92, P = 0.004). Although only minor effects on blood pressure were observed in this trial, an infrequent association of bupropion therapy and treatment-emergent hypertension cannot be ruled out...
  13. ncbi request reprint Selecting appropriate treatments for maintenance therapy for bipolar disorder
    Michael E Thase
    Department of Psychiatry, University of Pennsylvania School of Medicine and Philadelphia Veterans Affairs Medical Center, Philadelphia, PA 19104, USA
    J Clin Psychiatry 69:28-35. 2008
    ..Additionally, several forms of psychotherapy specifically tailored to the needs of people with bipolar disorder should be considered as an adjunct to medication...
  14. pmc Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies
    Michael E Thase
    Departments of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Prim Care Companion J Clin Psychiatry 10:440-7. 2008
    ..Patients with major depressive disorder (MDD) who fail to achieve complete remission with antidepressant therapy may benefit from augmentation therapy with an atypical antipsychotic...
  15. ncbi request reprint An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder
    Michael E Thase
    Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    CNS Spectr 14:144-54. 2009
    ..To assess the efficacy of desvenlafaxine (administered as desvenlafaxine succinate) in outpatients with major depressive disorder...
  16. ncbi request reprint Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder
    Michael E Thase
    Department of Psychiatry, University of Pennsylvania School of Medicine, 3535 Market Street, Philadelphia, PA 19104, USA
    J Clin Psychopharmacol 27:672-6. 2007
    ....
  17. doi request reprint Atypical depression: useful concept, but it's time to revise the DSM-IV criteria
    Michael E Thase
    Department of Psychiatry, University of Pennsylvania School of Medicine and Philadelphia Veterans Affairs Medical Center, Philadelphia, PA 15213 2593, USA
    Neuropsychopharmacology 34:2633-41. 2009
    ..Research examining the validity of a subform of atypical depression characterized by trait-like interpersonal sensitivity and a chronic, early-onset course may further enhance the clinical utility of the DSM-V classification...
  18. ncbi request reprint Do antidepressants really work? A clinicians' guide to evaluating the evidence
    Michael E Thase
    University of Pennsylvania School of Medicine, 3535 Market Street, Suite 670, Philadelphia, PA 19104, USA
    Curr Psychiatry Rep 10:487-94. 2008
    ....
  19. doi request reprint Update on partial response in depression
    Michael E Thase
    Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia Veterans Affairs Medical Center, and Pittsburgh Medical Center, Philadelphia and Pittsburgh, USA
    J Clin Psychiatry 70:4-9. 2009
    ..Although studies on predictive factors have not yielded definitive results, clinicians in practice often select adjunctive agents that target patients' persistent symptoms...
  20. doi request reprint The small specific effects of antidepressants in clinical trials: what do they mean to psychiatrists?
    Michael E Thase
    Philadelphia Veterans Affairs Medical Center, Perelman School of Medicine of the University of Pennsylvania, University of Pittsburgh Medical Center, 3535 Market Street, Suite 670, Philadelphia, PA 19104, USA
    Curr Psychiatry Rep 13:476-82. 2011
    ..Nevertheless, it is also concluded that the modest benefits of antidepressants in grouped datasets obscure large, specific, and very meaningful therapeutic effects for 10% to 20% of those treated with antidepressants...
  21. doi request reprint Assessing the 'true' effect of active antidepressant therapy v. placebo in major depressive disorder: use of a mixture model
    Michael E Thase
    University of Pennsylvania School of Medicine, and Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA USA
    Br J Psychiatry 199:501-7. 2011
    ..There is controversy about the implications of relatively small average drug-placebo differences observed in randomised controlled trials of antidepressant medications...
  22. doi request reprint Pharmacotherapy of mood disorders
    Michael E Thase
    University of Pennsylvania School of Medicine and Veterans Administration Medical Center, Philadelphia, Pennsylvania 19104, USA
    Annu Rev Clin Psychol 4:53-91. 2008
    ....
  23. ncbi request reprint Recognition and diagnosis of atypical depression
    Michael E Thase
    Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA 19380, USA
    J Clin Psychiatry 68:11-6. 2007
    ..Although introduction of safer MAOIs has fostered renewed interest in atypical depression, the validity and importance of the DSM-IV definition of atypical depression for the nosology of affective illness remains an open question...
  24. ncbi request reprint Antidepressant combinations: widely used, but far from empirically validated
    Michael E Thase
    University of Pennsylvania School of Medicine and Philadelphia Veterans Affairs Medical Center, Philadelphia 19104, USA
    Can J Psychiatry 56:317-23. 2011
    ....
  25. doi request reprint Comparing venlafaxine extended release and fluoxetine for preventing the recurrence of major depression: results from the PREVENT study
    Michael E Thase
    School of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 3309, United States
    J Psychiatr Res 45:412-20. 2011
    ..034). No significant between-group differences were observed with any of the secondary efficacy variables. Venlafaxine ER and fluoxetine were similarly well tolerated across 2 years of maintenance-phase therapy...
  26. ncbi request reprint Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression
    Michael E Thase
    University of Pennsylvania School of Medicine, 3535 Market Street, Suite 670, Philadelphia, PA 19104, USA
    Int Clin Psychopharmacol 25:189-98. 2010
    ..In conclusion, the findings indicate that mirtazapine may be a more rapidly effective antidepressant than SSRIs...
  27. pmc Which symptoms predict recurrence of depression in women treated with maintenance interpersonal psychotherapy?
    Alexandre Y Dombrovski
    Western Psychiatric Institute and Clinic, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Depress Anxiety 25:1060-6. 2008
    ..We therefore examined the impact of persistent symptoms, including mood, insomnia, and anxiety symptoms, on time to recurrence in women receiving maintenance interpersonal psychotherapy (IPT-M) for recurrent depression...
  28. ncbi request reprint Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combination
    Philip T Ninan
    Department of Psychiatry, Emory University School of Medicine, Atlanta, GA 30329, USA
    J Clin Psychiatry 63:434-41. 2002
    ....
  29. ncbi request reprint Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD
    Joseph F Goldberg
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
    J Clin Psychiatry 70:155-62. 2009
    ..Many patients with bipolar disorder receive multi-drug treatment regimens, but the distinguishing profiles of patients who receive complex pharmacologies have not been established...
  30. ncbi request reprint Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report
    Michael E Thase
    Department of Psychiatry, University of Pittsburgh Medical Center, 3811 OHara St, Pittsburgh, PA 15213 2593, and Massachusetts General Hospital, USA
    Am J Psychiatry 164:739-52. 2007
    ..Cognitive therapy was compared with medication augmentation and switch strategies...
  31. ncbi request reprint Pharmacotherapy of bipolar depression: an update
    Michael E Thase
    University of Pittsburgh Medical Center, Western Psychiatric Institute and Clinic, 3811 O Hara St, Pittsburgh, PA 15213 2593, USA
    Curr Psychiatry Rep 8:478-88. 2006
    ..Antidepressants--particularly selective serotonin reuptake inhibitors and bupropion--are indicated when mood stabilizers are ineffective and for "breakthrough" depressions...
  32. ncbi request reprint Medication augmentation after the failure of SSRIs for depression
    Madhukar H Trivedi
    Mood Disorder Program and Clinic, Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390 9119, USA
    N Engl J Med 354:1243-52. 2006
    ..Although clinicians frequently add a second medication to an initial, ineffective antidepressant drug, no randomized controlled trial has compared the efficacy of this approach...
  33. ncbi request reprint The state of knowledge of chronic depression
    Alan J Gelenberg
    Department of Psychiatry, Arizona Health Sciences Center, Tucson, AZ, USA
    J Clin Psychiatry 67:179-84. 2006
  34. ncbi request reprint The prospective course of rapid-cycling bipolar disorder: findings from the STEP-BD
    Christopher D Schneck
    Department of Psychiatry, University of Colorado Health Sciences Center, Denver, CO 80220, USA
    Am J Psychiatry 165:370-7; quiz 410. 2008
    ..In a naturalistic follow-up of adult bipolar patients, the authors examined the contributions of demographic, phenomenological, and clinical variables, including antidepressant use, to prospectively observed mood episode frequency...
  35. ncbi request reprint Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design
    A John Rush
    Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9086, USA
    Control Clin Trials 25:119-42. 2004
    ..Participants with an adequate symptomatic response may enter the 12-month naturalistic follow-up phase with brief monthly and more complete quarterly assessments...
  36. ncbi request reprint An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depression
    Madhukar H Trivedi
    Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390 9119, USA
    J Clin Psychiatry 70:387-96. 2009
    ..To evaluate the efficacy of olanzapine/fluoxetine combination (OFC) versus olanzapine or fluoxetine monotherapy across all clinical trials of treatment-resistant depression sponsored by Eli Lilly and Company...
  37. ncbi request reprint Clinical significance of lifetime panic spectrum symptoms in the treatment of patients with bipolar I disorder
    Ellen Frank
    Department of Psychiatry, Western Psychiatric Institute and Clinic, Pittsburgh, PA 15213, USA
    Arch Gen Psychiatry 59:905-11. 2002
    ..We hypothesized that lifetime panic spectrum features would be associated with higher levels of suicidal ideation and a poorer response to acute treatment of the index mood episode in this patient population...
  38. ncbi request reprint Optimizing treatment outcomes for patients with depression and generalized anxiety disorder
    Michael E Thase
    Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213 2593, USA
    Psychopharmacol Bull 36:93-102. 2002
    ....
  39. ncbi request reprint Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depression
    Alan J Gelenberg
    Department of Psychiatry, Health Sciences Center, University of Arizona, PO Box 245002, Tucson, AZ 85724 5002, USA
    Biol Psychiatry 54:806-17. 2003
    ..This randomized, placebo-controlled study of the efficacy and safety of nefazodone in preventing recurrence was conducted for patients with chronic MDD...
  40. doi request reprint What predicts attrition in second step medication treatments for depression?: a STAR*D Report
    Diane Warden
    Department of Psychiatry, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390 9119, USA
    Int J Neuropsychopharmacol 12:459-73. 2009
    ..Focus on patients with attrition risk factors for medication augmentation or switch strategies may enhance retention and improve outcomes...
  41. ncbi request reprint Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study)
    Michael E Thase
    Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA 15213 2593, USA
    J Clin Psychopharmacol 26:600-9. 2006
    ..This study demonstrates that quetiapine monotherapy is an effective and well-tolerated treatment for depressive episodes in bipolar disorder, confirming the results observed from a previous study (BipOLar DEpRession [BOLDER] I)...
  42. ncbi request reprint Acceptability of second-step treatments to depressed outpatients: a STAR*D report
    Stephen R Wisniewski
    Department of Psychiatry, Epidemiology Data Center, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, and Clinical Psychopharmacology Unit, Massachusetts General Hospital, Boston, USA
    Am J Psychiatry 164:753-60. 2007
    ..This study sought to identify factors that affect patients' willingness to accept different second-step treatment approaches...
  43. pmc Chronic forms of major depression are still undertreated in the 21st century: systematic assessment of 801 patients presenting for treatment
    James H Kocsis
    Department of Psychiatry, Weill Cornell Medical Center, 525 East 68th Street, New York, NY 10021, USA
    J Affect Disord 110:55-61. 2008
    ..These results and the consistency of similar results over time point to the dire need for patient and provider education regarding the signs and symptoms of depression and its treatment...
  44. doi request reprint Clinical features associated with poor pharmacologic adherence in bipolar disorder: results from the STEP-BD study
    Roy H Perlis
    Bipolar Clinic and Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 71:296-303. 2010
    ..Poor medication adherence is common among bipolar patients...
  45. pmc Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: the REVAMP Trial
    James H Kocsis
    Department of Psychiatry, Weill Cornell Medical College, 1300 York Ave, New York, NY 10065, USA
    Arch Gen Psychiatry 66:1178-88. 2009
    ..Previous studies have found that few chronically depressed patients remit with antidepressant medications alone...
  46. ncbi request reprint Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study
    James H Kocsis
    Department of Psychiatry, Weill Cornell Medical College, New York, NY 10012, USA
    J Clin Psychiatry 68:1014-23. 2007
    ..To test the long-term efficacy and safety of venlafaxine extended-release (ER) in preventing recurrence in patients with major depression...
  47. doi request reprint Income and attrition in the treatment of depression: a STAR*D report
    Diane Warden
    Department of Psychiatry, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390 9086, USA
    Depress Anxiety 26:622-33. 2009
    ..This report assessed whether attrition rates and predictors of attrition differed among depressed outpatients with different income levels...
  48. ncbi request reprint Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report
    A John Rush
    Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390 9086, USA
    Am J Psychiatry 163:1905-17. 2006
    ..This report describes the participants and compares the acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial...
  49. ncbi request reprint New approaches to managing difficult-to-treat depressions
    Michael E Thase
    Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    J Clin Psychiatry 64:3-4. 2003
    ..Challenging subtypes of illness, including psychotic and bipolar subtypes of depression, are not necessarily inherently refractory but must be met with modified treatment approaches...
  50. ncbi request reprint Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorder
    Lewis L Judd
    Department of Psychiatry, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA 92093 0603, USA
    Am J Psychiatry 161:1864-71. 2004
    ..Minor depressive disorder is both common and associated with significant psychosocial impairment. This study examined antidepressant treatment efficacy in a large group of patients with minor depressive disorder...
  51. ncbi request reprint Focus on bipolar disorder treatment
    Charles L Bowden
    Department of Psychiatry, University of Texas Health Science Center at San Antonio, TX, USA
    J Clin Psychiatry 66:1598-609. 2005
  52. ncbi request reprint Differential effects of treatments for chronic depression: a latent growth model reanalysis
    Niklaus Stulz
    Department of Psychiatry, University of Pennsylvania Philadelphia, PA 19104, USA
    J Consult Clin Psychol 78:409-19. 2010
    ....
  53. ncbi request reprint Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression
    A John Rush
    Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390 9086, USA
    N Engl J Med 354:1231-42. 2006
    ..After unsuccessful treatment for depression with a selective serotonin-reuptake inhibitor (SSRI), it is not known whether switching to one antidepressant is more effective than switching to another...
  54. ncbi request reprint Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder
    Ellen Frank
    Western Psychiatric Institute and Clinic, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    Arch Gen Psychiatry 62:996-1004. 2005
    ..Recent investigations have demonstrated benefits from the addition of psychoeducation or psychotherapy to pharmacotherapy in this population...
  55. ncbi request reprint Effect of age at onset on the course of major depressive disorder
    Sidney Zisook
    Department of Psychiatry, University of California, San Diego, CA 92093, USA
    Am J Psychiatry 164:1539-46. 2007
    ..This report assesses whether age at onset defines a specific subgroup of major depressive disorder in 4,041 participants who entered the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study...
  56. ncbi request reprint Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study
    Michael E Thase
    Division of Adult Academic Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    CNS Spectr 11:93-102. 2006
    ..Placebo-controlled studies indicate that modafinil, a wake-promoting agent, may relieve residual symptoms...
  57. ncbi request reprint Managing depressive and anxiety disorders with escitalopram
    Michael E Thase
    University of Pittsburgh Medical Centre, Western Psychiatric Institute and Clinic, Pittsburgh, PA 15213 2593, USA
    Expert Opin Pharmacother 7:429-40. 2006
    ..Pharmacoeconomic models suggest that the greater drug acquisition cost of this patent-protected compound may be offset by greater efficacy (relative to generic citalopram) and tolerability (compared with extended release venlafaxine)...
  58. ncbi request reprint Bipolar depression: issues in diagnosis and treatment
    Michael E Thase
    Department of Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
    Harv Rev Psychiatry 13:257-71. 2005
    ..The optimal duration of maintenance antidepressant therapy has not been established empirically and, until better evidence-based guidelines are established, should be determined on a case-by-case basis...
  59. ncbi request reprint Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactions
    Michael E Thase
    Department of Psychiatry, University of Pittsburgh Medical Center, Western Psychiatric Institute and Clinic, 3811 O Hara Street, Pittsburgh, PA 15213 2593, USA
    J Womens Health (Larchmt) 14:609-16. 2005
    ..To investigate whether differences in antidepressant efficacy are moderated by an interaction of age and gender...
  60. ncbi request reprint Augmentation strategies for depression: history and concepts
    Michael E Thase
    University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
    CNS Spectr 12:3-5. 2007
  61. doi request reprint Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STAR*D study
    Sidney Zisook
    Department of Psychiatry, University of California, San Diego, San Diego VA Medical Center, San Diego, California, USA
    J Affect Disord 117:63-73. 2009
    ..The purpose of this study was to determine whether, and in whom, treatment of MDD is associated with increased or emergent SI...
  62. ncbi request reprint Citalopram treatment of paroxetine-intolerant depressed patients
    Michael E Thase
    Department of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute Clinic, 3811 O Hara Street, Pittsburgh, PA 15213 2593, USA
    Depress Anxiety 16:128-33. 2002
    ....
  63. ncbi request reprint A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability
    Michael E Thase
    Department of Psychiatry, University of Pittsburgh Medical Center, Western Psychiatric Institute, Pittsburgh, PA, USA
    J Clin Psychopharmacol 26:482-8. 2006
    ..In conclusion, in this patient population (ie, relatively young, sexually active outpatients), bupropion XL was at least as effective as venlafaxine XR and had a significantly more favorable sexual side effect profile...
  64. ncbi request reprint A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder
    Michael E Thase
    Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    J Clin Psychiatry 68:224-36. 2007
    ..Two parallel, 8-week double-blind studies compared olanzapine/fluoxetine combination, olanzapine, and fluoxetine in outpatients with treatment-resistant depression (TRD)...
  65. ncbi request reprint What role do atypical antipsychotic drugs have in treatment-resistant depression?
    Michael E Thase
    Department of Psychiatry, University of Pittsburgh School of Medicine, PA, USA
    J Clin Psychiatry 63:95-103. 2002
    ..Although more studies will be required to confirm and extend these findings, the results suggest that there may be a clinical benefit to combining atypical antipsychotics with SSRIs in nonpsychotic TRD...
  66. ncbi request reprint Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatients
    A John Rush
    Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390 9086, USA
    Neuropsychopharmacology 30:405-16. 2005
    ..Global patient ratings such as the PGI-I, as opposed to specific item-based ratings, provide less valid findings...
  67. ncbi request reprint Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depression
    Michael E Thase
    Department of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, PA 15213 2593, USA
    J Clin Psychiatry 63:493-500. 2002
    ..As nefazodone-mediated blockade of serotonin-2 receptors may directly relieve insomnia associated with depression, we examined the more specific effects of CBASP and nefazodone, singly and in combination, on sleep disturbances...
  68. ncbi request reprint Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategies
    Michael E Thase
    University of Pittsburgh Medical Center, Department of Psychiatry, Pittsburgh, PA 15213 2593, USA
    J Clin Psychopharmacol 26:250-8. 2006
    ....
  69. ncbi request reprint Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combination
    John Zajecka
    Department of Psychiatry, Rush Presbyterian St Luke s Medical Center, 1725 W Harrison Street, Suite 955, Chicago, IL 60612, USA
    J Clin Psychiatry 63:709-16. 2002
    ..This study compares the effects of antidepressant medication, psychotherapy, and combined treatment on sexual interest/satisfaction and function in patients with chronic major depression...
  70. pmc Stability of symptoms across major depressive episodes in bipolar disorder
    Roy H Perlis
    Bipolar Clinic and Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Bipolar Disord 11:867-75. 2009
    ..These studies make the implicit assumption of stability of symptoms across episodes in mood disorders, which has rarely been investigated...
  71. ncbi request reprint Management of patients with treatment-resistant depression
    Michael E Thase
    Department of Psychiatry, University of Pittsburgh Medical Center, Western Psychiatric Institute and Clinic, Pittsburgh, PA, USA
    J Clin Psychiatry 69:e8. 2008
    ....
  72. ncbi request reprint Does recovery from substance use disorder matter in patients with bipolar disorder?
    Roger D Weiss
    Department of Psychiatry, Harvard Medical School, Boston, USA
    J Clin Psychiatry 66:730-5; quiz 808-9. 2005
    ..To examine the potential impact of recovery from substance use disorder (SUD) on the course of bipolar disorder among patients diagnosed with both bipolar and substance use disorders according to DSM-IV criteria...
  73. ncbi request reprint Patient preference as a moderator of outcome for chronic forms of major depressive disorder treated with nefazodone, cognitive behavioral analysis system of psychotherapy, or their combination
    James H Kocsis
    Department of Psychiatry, Weill Cornell Medical College, New York, N Y, USA
    J Clin Psychiatry 70:354-61. 2009
    ..We hypothesized that patient preference at baseline would interact with treatment group to differentially affect treatment outcome...
  74. ncbi request reprint Slower treatment response in bipolar depression predicted by lower pretreatment thyroid function
    Daniel P Cole
    Department of Psychiatry, University of Pittsburgh School of Medicine, USA
    Am J Psychiatry 159:116-21. 2002
    ..It was hypothesized that subjects with lower thyroid function, even within the normal range, would have a poorer response to initial treatment...
  75. ncbi request reprint Evaluating antidepressant therapies: remission as the optimal outcome
    Michael E Thase
    Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
    J Clin Psychiatry 64:18-25. 2003
    ..e., quantitative and pooled) suggest that both psychotherapy-pharmacotherapy combinations and use of antidepressants that enhance serotonergic and noradrenergic neurotransmission increase the likelihood of remission...
  76. ncbi request reprint Suicide attempts in patients with bipolar I disorder during acute and maintenance phases of intensive treatment with pharmacotherapy and adjunctive psychotherapy
    Paola Rucci
    Department of Psychiatry, Western Psychiatric Institite and Clinic, 3811 O Hara Street, Pittsburgh, PA 15213, USA
    Am J Psychiatry 159:1160-4. 2002
    ..Lifetime rates of suicide attempts among patients with bipolar I disorder were compared to rates during a 2-year period of intensive treatment with pharmacotherapy and with one of two adjunctive psychosocial interventions...
  77. ncbi request reprint A descriptive analysis of minor depression
    Mark Hyman Rapaport
    Department of Psychiatry, University of California, San Diego, School of Medicine, La Jolla, 92037, USA
    Am J Psychiatry 159:637-43. 2002
    ..The authors provide a detailed clinical description of minor depression: its symptoms, level of disability, stability, and relationship to patient and family history of major depressive disorder...
  78. ncbi request reprint First-line pharmacotherapies for depression - what is the best choice?
    Aaron M Koenig
    Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, United States
    Pol Arch Med Wewn 119:478-86. 2009
    ....
  79. ncbi request reprint Validity of the distinction between primary and secondary substance use disorder in patients with bipolar disorder: data from the first 1000 STEP-BD participants
    Mark D Fossey
    Department of Psychiatry, University of Oklahoma College of Medicine Tulsa, Tulsa, Oklahoma 74135, USA
    Am J Addict 15:138-43. 2006
    ..The primary/secondary distinction for SUD is not valid when variations in the age of onset of the non-SUD are linked to course characteristics...
  80. doi request reprint An open label pilot study of transcranial magnetic stimulation for pregnant women with major depressive disorder
    Deborah R Kim
    Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Womens Health (Larchmt) 20:255-61. 2011
    ..We present the results of an open label pilot study examining treatment with transcranial magnetic stimulation (TMS) in pregnant women with MDD...
  81. ncbi request reprint Mediators of outcome of psychosocial treatments for cocaine dependence
    Paul Crits-Christoph
    Department of Psychiatry, University of Pennsylvania, PA, USA
    J Consult Clin Psychol 71:918-25. 2003
    ..In addition, a measure of beliefs about addiction developed to test mediation of outcome of cognitive therapy was found to correlate moderately with drug use outcomes in both cognitive therapy and individual drug counseling...
  82. ncbi request reprint Therapeutic reactance as a predictor of outcome in the treatment of chronic depression
    Bruce A Arnow
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, California 94305 5722, USA
    J Consult Clin Psychol 71:1025-35. 2003
    ..Results support the importance of Aptitude * Treatment interactions in psychotherapy outcome. The direction and significance of such interactions may vary with different forms of psychopathology...
  83. ncbi request reprint Effectiveness of antidepressants: comparative remission rates
    Michael E Thase
    University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, Pittsburgh, PA 15213, USA
    J Clin Psychiatry 64:3-7. 2003
    ..Given the better tolerability of newer antidepressants relative to tricyclics, both logic and an increasing amount of data support a greater role for multiaction antidepressants...
  84. ncbi request reprint The effectiveness of St. John's Wort in major depressive disorder: a naturalistic phase 2 follow-up in which nonresponders were provided alternate medication
    Alan J Gelenberg
    University of Arizona Health Sciences Center, Tucson, AZ 85724, USA
    J Clin Psychiatry 65:1114-9. 2004
    ..A continuation study of an extract of St. John's wort (Hypericum perforatum) for depression was performed in follow-up to an acute study that found no significant difference between St. John's wort extract and placebo...
  85. ncbi request reprint Brief report: paroxetine in younger and adult individuals at high risk for suicide
    Mark S Bauer
    Department of Psychiatry, Brown University, USA
    Psychopharmacol Bull 39:31-7. 2006
    ..In fact, the younger group showed a trend for decreased suicidality (P = .13). Thus, increased suicidality risk with paroxetine exposure does not extend to this other high-risk mood disordered population, even among younger individuals...
  86. ncbi request reprint The effects of psychotherapy, nefazodone, and their combination on subjective assessment of disturbed sleep in chronic depression
    Rachel Manber
    Department of Psychiatry and Behavioral Sciences, Stanford University, CA 94305, USA
    Sleep 26:130-6. 2003
    ..The purpose of the study was to compare the effects of psychotherapy, nefazodone, and their combination on subjective measures of sleep in patients with chronic forms of major depression...
  87. ncbi request reprint A pilot study of brief interpersonal psychotherapy for depression among women
    Holly A Swartz
    Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Psychiatr Serv 55:448-50. 2004
    ..Both groups improved significantly over time, with large effect sizes. However, contrary to expectations, the women who received psychotherapy improved more quickly than those who received sertraline...
  88. ncbi request reprint Rates and symptoms of PTSD among cocaine-dependent patients
    Lisa M Najavits
    Harvard Medical School, Boston, Massachusetts, USA
    J Stud Alcohol 64:601-6. 2003
    ..This study evaluated lifetime traumatic events and current posttraumatic stress disorder (PTSD) symptoms in a substance abuse sample...
  89. ncbi request reprint Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study
    Ihsan M Salloum
    Western Psychiatric Institute and Clinic of the University of Pittsburgh Medical Center and School of Pharmacy, University of Pittsburgh, Pittsburgh, PA 15213, USA
    Arch Gen Psychiatry 62:37-45. 2005
    ..Patients with comorbid substance abuse disorders often are excluded from clinical trials. Thus, treatments targeting this high-risk clinical population are lacking...
  90. ncbi request reprint Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine
    Mikael Landen
    Section of Psychiatry St Göran, Department of Clinical Neuroscience, Karolinska Institutet, SE 112 81, Stockholm, Sweden
    J Clin Psychiatry 66:100-6. 2005
    ....
  91. ncbi request reprint Self-reported history of manic/hypomanic switch associated with antidepressant use: data from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)
    Christine J Truman
    Finney Psychotherapy Associates, Norfolk, VA, USA
    J Clin Psychiatry 68:1472-9. 2007
    ....
  92. ncbi request reprint Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs
    Charles B Nemeroff
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Biol Psychiatry 63:424-34. 2008
    ..To compare venlafaxine and selective serotonin reuptake inhibitors (SSRIs; fluoxetine, sertraline, paroxetine, fluvoxamine, and citalopram) in the treatment of depression...
  93. ncbi request reprint The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: Outcomes from the 2-year and combined maintenance phases
    Martin B Keller
    Department of Psychiatry and Human Behavior, Brown University, Providence, RI 02906, USA
    J Clin Psychiatry 68:1246-56. 2007
    ..To report second-year results from the 2-year maintenance phase of a long-term study to evaluate the efficacy and safety of venlafaxine extended release (ER) in preventing recurrence of depression...
  94. ncbi request reprint The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phases
    Martin B Keller
    Brown University, Providence, Rhode Island 02906, USA
    Biol Psychiatry 62:1371-9. 2007
    ..We evaluated the comparative efficacy and safety of venlafaxine extended release (ER) and fluoxetine in the acute and continuation phases of treatment...
  95. ncbi request reprint Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: findings from the STEP-BD
    Joseph F Goldberg
    Affective Disorders Program, Silver Hill Hospital, New Canaan, Connecticut, USA
    Am J Psychiatry 164:1348-55. 2007
    ..However, few studies have examined the outcomes of patients with co-occurring manic and depressive symptoms who are treated with antidepressants plus mood stabilizing drugs...
  96. pmc Intensive psychosocial intervention enhances functioning in patients with bipolar depression: results from a 9-month randomized controlled trial
    David J Miklowitz
    Department of Psychology, University of Colorado, Boulder, CO 80309 0345, USA
    Am J Psychiatry 164:1340-7. 2007
    ..In a randomized trial, the authors examined the impact of intensive psychosocial treatment plus pharmacotherapy on the functional outcomes of patients with bipolar disorder over the 9 months following a depressive episode...
  97. ncbi request reprint Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report
    Patrick J McGrath
    Depression Evaluation Service, New York State Psychiatric Institute, 1051 Riverside Dr, New York, NY 10032, USA
    Am J Psychiatry 163:1531-41; quiz 1666. 2006
    ....
  98. ncbi request reprint A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder
    David G S Perahia
    Lilly Research Centre, Erl Wood, Sunninghill Road, Windlesham, Surrey GU20 6PH, UK
    J Psychiatr Res 42:22-34. 2008
    ..The objective was to compare the serotonin and norepinephrine reuptake inhibitors (SNRIs) duloxetine and venlafaxine using GBR assessment...
  99. ncbi request reprint Effectiveness of adjunctive antidepressant treatment for bipolar depression
    Gary S Sachs
    Bipolar Clinic and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    N Engl J Med 356:1711-22. 2007
    ..Our study was designed to determine whether adjunctive antidepressant therapy reduces symptoms of bipolar depression without increasing the risk of mania...
  100. ncbi request reprint Comparing the rapidity of response during treatment of major depressive disorder with bupropion and the SSRIs: a pooled survival analysis of 7 double-blind, randomized clinical trials
    George I Papakostas
    Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Psychiatry 68:1907-12. 2007
    ..The current analysis was undertaken to determine if these antidepressants differ in rapidity of clinical effect...
  101. ncbi request reprint Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)
    Roy H Perlis
    Bipolar Clinical and Research Program, Massachusetts General Hospital, ACC 812, 15 Parkman Street, Boston, MA 02114, USA
    Am J Psychiatry 163:217-24. 2006
    ..The authors looked for the features associated with risk of recurrence...

Research Grants16

  1. PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSION
    Michael Thase; Fiscal Year: 2009
    ....
  2. PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSION
    Michael Thase; Fiscal Year: 2000
    ..Blind evaluations occur at the end of the acute phase and at four and eight months post-acute phase CT, as well as at suspected relapse or exit. Survival analyses are planned. ..
  3. PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSION
    Michael E Thase; Fiscal Year: 2010
    ....
  4. PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSION
    Michael Thase; Fiscal Year: 2007
    ....
  5. Are Cognitive Therapy's Antidepressant Effects Durable?
    Michael Thase; Fiscal Year: 2007
    ..Dependent variables measure response, relapse, recurrence, remission, and recovery. Blind evaluations and survival analysis are planned. ..
  6. PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSION
    Michael Thase; Fiscal Year: 2006
    ....
  7. Are Cognitive Therapy's Antidepressant Effects Durable?
    Michael Thase; Fiscal Year: 2006
    ..Dependent variables measure response, relapse, recurrence, remission, and recovery. Blind evaluations and survival analysis are planned. ..
  8. PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSION
    Michael Thase; Fiscal Year: 2005
    ..Specifically, if C-CT is significantly more effective than PBO at the end of "Phase 1," then FLX must also have therapeutic activity. ..
  9. PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSION
    Michael Thase; Fiscal Year: 2004
    ..Blind evaluations occur at the end of the acute phase and at four and eight months post-acute phase CT, as well as at suspected relapse or exit. Survival analyses are planned. ..
  10. Are Cognitive Therapy's Antidepressant Effects Durable?
    Michael Thase; Fiscal Year: 2005
    ..Dependent variables measure response, relapse, recurrence, remission, and recovery. Blind evaluations and survival analysis are planned. ..
  11. Are Cognitive Therapy's Antidepressant Effects Durable?
    Michael Thase; Fiscal Year: 2004
    ..Dependent variables measure response, relapse, recurrence, remission, and recovery. Blind evaluations and survival analysis are planned. ..
  12. PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSION
    Michael Thase; Fiscal Year: 2003
    ..Blind evaluations occur at the end of the acute phase and at four and eight months post-acute phase CT, as well as at suspected relapse or exit. Survival analyses are planned. ..
  13. PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSION
    Michael Thase; Fiscal Year: 2002
    ..Blind evaluations occur at the end of the acute phase and at four and eight months post-acute phase CT, as well as at suspected relapse or exit. Survival analyses are planned. ..
  14. PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSION
    Michael Thase; Fiscal Year: 2001
    ..Blind evaluations occur at the end of the acute phase and at four and eight months post-acute phase CT, as well as at suspected relapse or exit. Survival analyses are planned. ..
  15. 1/2-Efficacy of Computer-Assisted Cognitive Behavior Therapy for Depression
    Michael E Thase; Fiscal Year: 2010
    ..The proposed study will test the therapeutic equivalence and cost-effectiveness of CCBT versus CBT across a 16 week acute phase and a 6 month follow-up. ..